Laparotomy and Proximal Gastric Vagotomy in Zollinger-Ellison Syndrome: Results of a 16-year Prospective Study
Overview
Affiliations
Objective: Pharmacological control of gastric acid hypersecretion in the Zollinger-Ellison syndrome has steadily improved, but medical treatment does not address the underlying tumor. The objective of this study was to evaluate the long-term effectiveness of a surgical approach to both tumor and acid hypersecretion in 22 patients with the Zollinger-Ellison syndrome.
Methods: Patients underwent laparotomy to resect tumors, combined with vagotomy to reduce acid secretion, followed by postoperative antisecretory therapy, if necessary.
Results: No surgical mortality or serious morbidity occurred. Tumor was found at laparotomy in nine patients (41%) and during long-term follow-up in an additional two patients (9%). Ten-year survival is 81%, with a long-term cure rate of at least 14%. Most patients (86%) have had long-term inhibition of acid secretion. Eight patients have discontinued regular use of acid-inhibiting medications. Patients requiring medication need less of it, and they have an improved acid inhibitory response to medication for up to 16 yr after surgery.
Conclusion: Cure of the Zollinger-Ellison syndrome is possible in a minority of patients. Acid secretion can be safely reduced in almost all patients with laparotomy/vagotomy, usually allowing discontinuation, or reduced dose, of acid-inhibiting drugs. Long-term survival and quality of life are generally excellent.
Ito T, Ramos-Alvarez I, Jensen R Int J Mol Sci. 2024; 25(13).
PMID: 39000391 PMC: 11242121. DOI: 10.3390/ijms25137286.
Gastric Hypersecretory States: Investigation and Management.
Phan J, Benhammou J, Pisegna J Curr Treat Options Gastroenterol. 2015; 13(4):386-97.
PMID: 26342486 PMC: 4633316. DOI: 10.1007/s11938-015-0065-8.
Berna M, Hoffmann K, Serrano J, Gibril F, Jensen R Medicine (Baltimore). 2006; 85(6):295-330.
PMID: 17108778 PMC: 9806863. DOI: 10.1097/01.md.0000236956.74128.76.
Norton J, Jensen R Ann Surg. 2004; 240(5):757-73.
PMID: 15492556 PMC: 1356480. DOI: 10.1097/01.sla.0000143252.02142.3e.
Li M, Norton J Curr Treat Options Oncol. 2002; 2(4):337-46.
PMID: 12057114 DOI: 10.1007/s11864-001-0027-3.